Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(366)
•••
Post by moneywagonon Nov 09, 2022 10:19am
64 Views
Post# 35085120

BIOV 700K VOLUME INCOMING FIRST HALF HOUR~GUNNA BE G8 DAY!!

BIOV 700K VOLUME INCOMING FIRST HALF HOUR~GUNNA BE G8 DAY!!
C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   46.5 0.135 · 0.145 23.5 0.14 -0.02 -12.5 641.3 87 136 0.16  0.16  0.13 0.395  0.085 09:52:53 Oct 14 15 min RT 2¢
CSE - C 46.5 0.135 · 0.145 23.5 0.135 -0.025 -15.6 495.4 68 91 0.16  0.16  0.13 0.395  0.085 09:52:53   15 min 
NEO ATS - U   0.14 -0.02 -12.5 61.5 8 15 0.155  0.155  0.13   09:52:53   15 min 
Omega - O   0.14 -0.02 -12.5 56.5 8 13 0.155  0.155  0.135   09:52:53   15 min 
CX2 - H   0.13 -0.03 -18.8 26.5 3 7 0.145  0.145  0.13   09:40:02   15 min 
CXD - D   0.16     0.6   3        Jul 04   15 min 
TriAct - M   0.16     0.8   7            15 min 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities